1. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. (May 2018) Authors: Ploquin, A.; Pistilli, B.; Tresch, E.; Frenel, J.S.; Lerebours, F.; Lesur, A.; Loustalot, C.; Bachelot, T.; Provansal, M.; Ferrero, J.M.; Coussy, F.; Debled, M.; Kerbrat, P.; Vinceneux, A.; Allouache, D.; Morvan, F.; Dalenc, F.; Guiu, S.; Rouzier, R.; Vanlemmens, L. Journal: European journal of cancer Issue: Volume 95(2018) Page Start: 30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials. (April 2018) Authors: Lerebours, F.; Pulido, M.; Fourme, E.; Debled, M.; Becette, V.; Bonnefoi, H.; Rivera, S.; Mac Grogan, G.; Mouret-Reynier, M.A.; Tunon de Lara, C.; Pierga, J.Y.; Breton-Callu, C.; Venat-Bouvet, L.; Mathoulin-Pelissier, S.; Kerbrat, P.; Dalenc, F.; Sigal, B.; Bachelot, T.; Lemonnier, J.; Lerebours, Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. (18th October 2016) Authors: Pierga, J.-Y.; Bidard, F.-C.; Autret, A.; Petit, T.; Andre, F.; Dalenc, F.; Levy, C.; Ferrero, J.-M.; Romieu, G.; Bonneterre, J.; Lerebours, F.; Bachelot, T.; Kerbrat, P.; Campone, M.; Eymard, J.-C.; Mouret-Reynier, M.-A.; Gligorov, J.; Hardy-Bessard, A.-C.; Lortholary, A.; Soulie, P. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Issue 3 (1st May 2008) Authors: Pautier, P.; Gutierrez-Bonnaire, M.; Rey, A.; Sillet-Bach, I.; Chevreau, C.; Kerbrat, P.; Morice, P.; Duvillard, P.; Lhommé, C. Journal: International journal of gynecological cancer Issue: Volume 18:Issue 3(2008) Page Start: 446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. (December 2017) Authors: Loriot, Y.; Pagliaro, L.; Fléchon, A.; Mardiak, J.; Geoffrois, L.; Kerbrat, P.; Chevreau, C.; Delva, R.; Rolland, F.; Theodore, C.; Roubaud, G.; Gravis, G.; Eymard, J.C.; Malhaire, J.P.; Linassier, C.; Habibian, M.; Martin, A.L.; Journeau, F.; Reckova, M.; Logothetis, C. Journal: European journal of cancer Issue: Volume 87(2017) Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗